‹ ›
MYP_167060
← PREVIOUS NEXT → BACK
Basic Information
EK1-GSGSGC
Anticancer ▸ Cytotoxic anticancer activity ▸ Cytotoxic
Antimicrobial
Antiviral
Antiviral ▸ Anti-Coronavirus ▸ Anti-SARS-CoV
Antiviral ▸ Anti-Coronavirus ▸ Anti-SARS-CoV-2
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition
Enzyme modulation ▸ Enzyme inhibition ▸ Infection inhibition
Membrane / Ion-channel modulation ▸ Sodium channel modulation ▸ Sodium channel inhibitor
Toxicity / Safety ▸ Cytotoxicity ▸ Cytotoxic
Venom / Toxin ▸ General toxin ▸ Cytotoxic
Standard
42 amino acids
C211H341N49O72S2
Standard
Sequence
SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSGSGC
Physicochemical Analysis
4780.38 Da
4.36
-5.53
-5.78
-0.1318
-0.38
0.75
-0.01
20.91
102.14
0.0714
2980.00
2980.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
1987.31
-16.26
68.0
69.0
171.0
334.0
3.0
43.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0095945 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antimicrobial Anti-SARS-CoV-2
inhibition of infection in Vero E6 cells
IC50
PMID33082259 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/33082259/
RECORD: Rec_0121138 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antiviral Anti-SARS-CoV-2 Fusion inhibition
SARS-CoV-2_S247R | 293T cells
0.893±0.077 μM
IC90
Mammalian: 1.9 h; Yeast: >20 h; E. coli: >10 h
PaperInhibition of Coronavirus Entry In Vitro and Ex Vivo by a Lipid-Conjugated Peptide Derived from the SARS-CoV-2 Spike Glycoprotein HRC Domain. | Outlaw VK, Bovier FT, Mears MC, Cajimat MN, Zhu Y, Lin MJ, Addetia A, Lieberman NAP, Peddu V, Xie X, Shi PY, Greninger AL, Gellman SH, Bente DA, Moscona A, Porotto M. | mBio. 2020 Oct 20;11(5):e01935-20. | DOI:10.1128/mBio.01935-20 | PMID:33082259 PMID33082259 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/33082259/
RECORD: Rec_0159147 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antimicrobial Anti-SARS-CoV-2 Cytotoxic
Vero E6 cells
PMID33082259 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/33082259/
RECORD: Rec_0202007 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antiviral Anti-SARS-CoV-2 Fusion inhibition
SARS-CoV-2 | 293T cells
0.9 μM
IC90
Mammalian: 1.9 h; Yeast: >20 h; E. coli: >10 h
PaperInhibition of Coronavirus Entry In Vitro and Ex Vivo by a Lipid-Conjugated Peptide Derived from the SARS-CoV-2 Spike Glycoprotein HRC Domain. | Outlaw VK, Bovier FT, Mears MC, Cajimat MN, Zhu Y, Lin MJ, Addetia A, Lieberman NAP, Peddu V, Xie X, Shi PY, Greninger AL, Gellman SH, Bente DA, Moscona A, Porotto M. | mBio. 2020 Oct 20;11(5):e01935-20. | DOI:10.1128/mBio.01935-20 | PMID:33082259 PMID33082259 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/33082259/
RECORD: Rec_0217759 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antimicrobial Anti-SARS-CoV-2
SARS-CoV-2_S943P:inhibition of cell-cell fusion in 293T cells
0.286±0.104 μM
IC50
PMID33082259 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/33082259/
FIRST PREV 1 2 3 4 5 NEXT LAST
Showing 5 records on this page · Page 2 of 5